Results from a prospective clinical utility study of its Myriad myPath Melanoma test were presented by Myraid Genetics at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a genetic test that differentiates malignant melanoma from benign skin lesions across all major melanoma subtypes. Key findings of this clinical utility study included a 43 percent reduction in indeterminate diagnoses and a 49 percent ...Saturday 8 November 2014
Myriad MyPath Melanoma Test Improves Diagnosis and Treatment Plans
Results from a prospective clinical utility study of its Myriad myPath Melanoma test were presented by Myraid Genetics at the 2014 American Society of Dermatopathology (ASDP) annual meeting in Chicago, Ill. Myriad myPath Melanoma is a genetic test that differentiates malignant melanoma from benign skin lesions across all major melanoma subtypes. Key findings of this clinical utility study included a 43 percent reduction in indeterminate diagnoses and a 49 percent ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment